30 results on '"Castellano, Daniel"'
Search Results
2. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
3. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
4. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
5. Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
6. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
7. Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review
8. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
9. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
10. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
11. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
12. Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
13. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
14. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
15. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
16. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
17. Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
18. The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation
19. The role of pharmacogenomics in metastatic renal cell carcinoma
20. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
21. Castration-resistant metastatic prostate cancer: current status and treatment possibilities
22. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
23. Future perspectives on neuroendocrine tumors
24. Current knowledge on diagnosis and staging of neuroendocrine tumors
25. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations
26. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer
27. Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia
28. The optimize project: beyond first-line therapy in metastatic renal cell carcinoma
29. Erratum to: The role of pharmacogenomics in metastatic renal cell carcinoma
30. Gastroenteropancreatic neuroendocrine tumors. Where are we now?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.